The contribution of risk prediction models to early detection of lung cancer

Journal of Surgical Oncology

Volumn 108, Issue 5, 2013, Pages 304-311

  Field, John K ^a   Chen, Ying ^a   Marcus, Michael W ^a   McRonald, Fiona E ^a   Raji, Olaide Y ^a   Duffy, Stephen W ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

early diagnosis; lung neoplasms; risk assessment; screening; statistical model

Indexed keywords

AREA UNDER THE CURVE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CAUCASIAN; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; LOW ENERGY RADIATION; LUNG CANCER; POPULATION; POPULATION RESEARCH; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SMOKING;

EARLY DIAGNOSIS; LUNG NEOPLASMS; RISK ASSESSMENT; SCREENING; STATISTICAL MODEL;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MODELS, STATISTICAL; RISK; RISK REDUCTION BEHAVIOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84884910267     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23384     Document Type: Review

References (52)

1. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Schiller JH, Harrington D, Belani CP, et al.: Eastern cooperative oncology group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
3. van Rens MT, de la Riviere AB, Elbers HR, et al.: Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, IIIA. Chest 2000; 117: 374-379.
4. Ganti AK, Mulshine JL:, Lung cancer screening: Panacea or pipe dream ? Ann Oncol 2005; 16 Suppl 2: ii 215-219.
5. The National Lung Screening Trial Research Team. Reduced lung- cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
6. van Iersel CA, de Koning HJ, Draisma G, et al.: Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007; 120: 868-874.
7. Lopes Pegne A, Picozzi G, Mascalchi M:, Design, recruitment, and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer 2009; 64: 34-40.
8. Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: Three-year results from the DANTE trial. Am J Respir Crit Care Med 2009; 180: 445-453.
9. Blanchon T, Brechot JM, Grenier PA, et al.: Baseline results of the Depiscan study: A French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer 2007; 58: 50-58.
10. Pedersen J, Ashraf H, Dirksen A, et al.: The Danish randomized lung cancer CT screening trial-overal design and results of the prevalence round. J Thorac Oncol 2009; 5: 608-614.
11. Baldwin DR, Duffy SW, Wald NJ, et al.: UK lung screen (UKLS) nodule management protocol: Modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 2011; 66: 308-313.
12. Cassidy A, Myles JP, van Tongeren M, et al.: The LLP risk model: An individual risk prediction model for lung cancer. Br J Cancer 2008; 98: 270-276.
13. Raji OY, Duffy SW, Agbaje OF, et al.: Predictive accuracy of the liverpool lung project risk model for stratifying patients for computed tomography screening for lung cancer. Ann Intern Med 2012; 157: 242-250.
14. Vansteenkiste J, Dooms C, Mascaux C, et al.: Screening and early detection of lung cancer. Ann Oncol 2012; 23: x320-x327.
15. Centers for Disease Control and Prevention (CDC). Annual smoking-attributable mortality, years of potential life lost, and productivity losses: United States, 1997-2001. Morb Mortal Wkly Rep 2005; 54: 625-628.
16. McCarthy WJ, Meza R, Jeon J, et al.: Lung cancer in never smokers: Epidemiology and risk prediction models. Risk Anal 2012; 32: S69-S84.
17. Brennan P, Hainaut P, Boffetta P:, Genetics of lung-cancer susceptibility. Lancet Oncol 2011; 12: 399-408.
18. Duffy SW, Raji OY, Agbaje OF, et al.: Use of lung cancer risk models in planning research and service programs in CT screening for lung cancer. Expert Rev Anticancer Ther 2009; 9: 1467-1472.
19. Cassidy A, Duffy SW, Myles JP, et al.: Lung cancer risk prediction: A tool for early detection. Int J Cancer 2006; 120: 1-6.
20. Colditz GA, Atwood KA, Emmons E, et al.: Harvard report on cancer prevention volume 4: Harvard cancer risk index. Risk index working group, Harvard center for cancer prevention. Cancer Causes Control 2000; 11: 477-488.
21. Van Klaveren RJ, de Koning HJ, Mulshine J, et al.: Lung cancer screening by spiral CT. What is the optimal target population for screening trials ? Lung Cancer 2002; 38: 243-252.
22. Bach PB, Kattan MW, Thornquist MD, et al.: Variations in lung cancer risk among smokers. JNCI 2003; 95: 470-478.
23. Cronin KA, Gail MH, Zou Z, et al.: Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst 2006; 98: 637-640.
24. Spitz MR, Hong WK, Amos CI, et al.: A risk model for prediction of lung cancer. J Natl Cancer Inst 2007; 99: 715-726.
25. Vickers AJ, Cronin AM, Elkin EB, et al.: Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak 2008; 8: 53.
26. Vickers AJ, Elkin EB:, Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 2006; 26: 565-574.
27. Baker SG:, Putting risk prediction in perspective: Relative utility curves. J Natl Cancer Inst 2009; 101: 1538-1542.
28. Baker SG, van Calster B, Steyerberg EW:, Evaluating a new marker for risk prediction using the test tradeoff: An update. Int J Biostat 2012; 8: pii: /j/ijb.2012.8.issue-1/1557-4679.1395/1557-4679.1395.xml. doi: 10.1515/1557-4679.1395. See also "http://www.ncbi.nlm.nih.gov/pubmed/ 22499728".
29. D'Amelio AM,Jr, Cassidy A, Asomaning K, et al.: Comparison of discriminatory power and accuracy of three lung cancer risk models. Br J Cancer 2010; 103: 423-429.
30. Peto R, Darby S, Deo H, et al.: Smoking, smoking cessation, and lung cancer in the UK since 1950: Combination of national statistics with two case-control studies. BMJ 2000; 321: 323-329.
31. Gohagan JK, Prorok PC, Hayes RB, et al.: Prostate, lung, colorectal and ovarian cancer screening trial project team. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the National cancer institute: History, organization, and status. Control Clin Trials 2000; 21: 251S-272S.
32. Tammemagi CM, Pinsky PF, Caporaso NE, et al.: Lung cancer risk prediction: Prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst 2011; 103: 1058-1068.
33. Tammemagi MC, Katki HA, Hocking WG, et al.: Selection criteria for lung-cancer screening. N Engl J Med 2013; 368: 728-736.
34. Hoggart C, Brennan P, Tjonneland A, et al.: A risk model for lung cancer incidence. Cancer Prev Res 2012; 5: 834-846.
35. Etzel CJ, Kachroo S, Liu M, et al.: Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res 2008; 1: 255-265.
36. Park S, Nam BH, Yang HR, et al.: Individualized risk prediction model for lung cancer in Korean men. PLoS ONE 2013; 8: e54823.
37. Zhou W, Christiani DC:, East meets West: Ethnic differences in epidemiology and clinical behaviours of lung cancer between East Asians and Caucasians. Clin J Cancer 2011; 30: 287-292.
38. Punturieri A, Szabo E, Croxton TL, et al.: Lung cancer and chronic obstructive pulmonary disease: Needs and opportunities for integrated research. J Natl Cancer Inst 2009; 101: 554-559.
39. Field JK, Raji OY:, The potential for using risk models in future lung cancer screening trials. F1000 Med Rep 2010; 2: doi:pii: 38 See also "http://www.ncbi.nlm.nih.gov/pubmed/20948847".
40. Tockman MS, Gupta PK, Myers JD, et al.: Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: A new approach to early lung cancer detection. J Clin Oncol 1988; 6: 1685-1693.
41. Prindiville SA, Byers T, Hirsch FR, et al.: Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 2003; 12: 987-993.
42. Tammemagi MC, Lam SC, McWilliams AM, et al.: Incremental value of pulmonary function and sputum DNA image cytometry in lung cancer risk prediction. Cancer Prev Res 2011; 4: 552-561.
43. Spitz MR, Etzel CJ, Dong Q, et al.: An expanded risk prediction model for lung cancer. Cancer Prev Res 2008; 1: 250-254.
44. Raji OY, Agbaje OF, Duffy SW, et al.: Incorporation of a genetic factor into an epidemiologic model for prediction of individual risk of lung cancer: The liverpool lung project. Cancer Prev Res 2010; 3: 664-669.
45. Park JH, Gail MH, Greene MH, et al.: Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: An evaluation of seven common cancers. J Clin Oncol 2012; 30: 2157-2162.
46. Janssens AC, Aulchenko YS, Elefante S, et al.: Predictive testing for complex diseases using multiple genes: Fact or fiction ? Genet Med 2006; 8: 395-400.
47. Field JK:, Lung cancer risk models come of age. Cancer Prev Res 2008; 1: 226-228.
48. Nikolaidis G, Raji OY, Markopoulou S, et al.: DNA methylation biomarkers off improved diagnostic efficiency in lung cancer. Cancer Res 2012; 72: 5692-5701.
49. Taylor JMG, Ankerst DP, Andridge RR:, Validation of biomarker-based risk prediction models. Clin Cancer Res 2008; 14: 5977-6983.
50. Richards MA:, The National awareness and early diagnosis initiative in England: Assembling the evidence. Br J Cancer 2009; 101: s1-s4.
51. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497. See this web link "http://www.ncbi.nlm.nih.gov/ pubmed/11368702".
52. Pepe MS, Janes HE:, Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer (Editorial). J Natl Cancer Inst 2008; 100: 978-979.